ES2380201T3 - Derivados de benzimidazol - Google Patents
Derivados de benzimidazol Download PDFInfo
- Publication number
- ES2380201T3 ES2380201T3 ES04739891T ES04739891T ES2380201T3 ES 2380201 T3 ES2380201 T3 ES 2380201T3 ES 04739891 T ES04739891 T ES 04739891T ES 04739891 T ES04739891 T ES 04739891T ES 2380201 T3 ES2380201 T3 ES 2380201T3
- Authority
- ES
- Spain
- Prior art keywords
- hal
- group
- independently
- independently selected
- conh2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de benzimidazol de fórmula I donde R6, R7 son independientemente entre sí H o A, A se selecciona independientemente entre el grupo compuesto por alquilo, alcoxi y alcoxialquilo, R8 se selecciona entre un grupo compuesto por H, A, cicloalquilo que comprende de 3 a 7 átomos de carbono, Hal, CH2Hal, CH (Hal) 2, C (Hal) 3, NO2 y (CH2) nCN, R9 y R10 se seleccionan independientemente entre un grupo compuesto por H, A, cicloalquilo que comprende de 3 a 7 átomos de carbono, Hal, CH2Hal, CH (Hal) 2, C (Hal) 3, NO2, (CH2) nCN, (CH2) nNR11R12, (CH2) nOR11, (CH2) nO (CH2) kNR11R12, (CH2) nCOOR12, (CH2) nCONR11R12, (CH2) nNR11COR13, (CH2) nNR11CONR11R12, (CH2) nNR11SO2A, (CH2) nSO2NR11R12, (CH2) nS (O) uR13, (CH2) nOC (O) R13, (CH2) nCOR13, (CH2) nSR11, CH=N-OA, CH2CH=N-OA, (CH2) nNHOA, (CH2) nCH=N-R11, (CH2) nOC (O) NR11R12, (CH2) nNR11COOR12, (CH2) nN (R11) CH2CH2OR13, (CH2) nN (R11) CH2CH2OCF3, (CH2) nN (R11) C (R13) HCOOR12, C (R13) HCOR12, (CH2) nN (R11) CH2CH2N (R12) CH2COOR12, (CH2) nN (R11) CH2CH2NR11R12, CH=CHCOOR11, CH=CHCH2NR11R12, CH=CHCH2NR11R12, CH=CHCH2OR13, (CH2) nN (COOR11) COOR12, (CH2) nN (CONH2) COOR11, (CH2) nN (CONH2) CONH2, (CH2) nN (CH2COOR11) COOR12, (CH2) nN (CH2CONH2) COOR11, (CH2) nN (CH2CONH2) CONH2, (CH2) nCHR13COR11, (CH2) nCHR13COOR11, (CH2) nCHR13CH2OR14, (CH2) nOCN y (CH2) nNCO, donde R11, R12 se seleccionan independientemente entre un grupo compuesto por H, A, (CH2) mAr3 y (CH2) mHet, o en NR11R12 R11 y R12 forman, junto con el átomo de N al que están unidos, un heterociclo de 5, 6 o 7 átomos que contiene opcionalmente 1 o 2 heteroátomos adicionales, seleccionados entre N, O y S, R13, R14 se seleccionan independientemente entre un grupo compuesto por H, Hal, A, (CH2) mAr4 y (CH2) mHet, Ar3, Ar4 son independientemente entre sí restos de hidrocarburos aromáticos que comprenden de 5 a 12 y, preferiblemente, de 5 a 10 átomos de carbono que opcionalmente están sustituidos con uno o más sustituyentes, seleccionados entre un grupo compuesto por A, Hal, NO2, CN, OR15, NR15R16, COOR15, CONR15R16, NR15COR16, NR15CONR15R16, NR16SO2A, COR15, SO2R15R16, S (O) uA y OOCR15, Het es un resto heterocíclico saturado, insaturado o aromático que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre un grupo compuesto por A, Hal, NO2, CN, OR15, NR15R16, COOR15, CONR15R16, NR15COR16, NR15CONR15R16, NR16SO2A, COR15, SO2R15R16, S (O) uA y OOCR15, R15, R16 se seleccionan independientemente entre un grupo compuesto por H, A y (CH2) mAr6 donde Ar6 es un hidrocarburo aromático de 5 o 6 átomos que opcionalmente está sustituido con uno o más sustituyentes seleccionados entre un grupo compuesto por metilo, etilo, propilo, 2-propilo, terc-butilo, Hal, CN, OH, NH2 y CF3. 50 k, m y n son independientemente entre sí 0, 1, 2, 3, 4 o 5, R21 se selecciona independientemente entre las definiciones dadas para R13, R14 y p, r son independientemente entre sí 0, 1, 2, 3, 4 o 5, q es 0, 1, 2, 3 o 4, u es 0, 1, 2 o 3, y Hal se selecciona independientemente entre un grupo compuesto por F, Cl, Br y I; y las sales y solvatos fisiológicamente aceptables de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03015582 | 2003-07-11 | ||
| EP03015582 | 2003-07-11 | ||
| PCT/EP2004/006419 WO2005004864A1 (en) | 2003-07-11 | 2004-06-15 | Benzimidazole derivatives as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2380201T3 true ES2380201T3 (es) | 2012-05-09 |
Family
ID=34042825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04739891T Expired - Lifetime ES2380201T3 (es) | 2003-07-11 | 2004-06-15 | Derivados de benzimidazol |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7691886B2 (es) |
| EP (1) | EP1653951B1 (es) |
| JP (1) | JP4823903B2 (es) |
| AR (1) | AR045895A1 (es) |
| AT (1) | ATE538787T1 (es) |
| CA (1) | CA2531859C (es) |
| ES (1) | ES2380201T3 (es) |
| WO (1) | WO2005004864A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00275B (me) | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| JP5001650B2 (ja) * | 2003-07-11 | 2012-08-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンズイミダゾールカルボキサミド |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| CA2716947A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| KR20100122505A (ko) * | 2008-02-29 | 2010-11-22 | 어레이 바이오파마 인크. | Ｒａｆ 저해물질 화합물 및 이들의 이용 방법 |
| JP2011513331A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤 |
| US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| CN102712601A (zh) * | 2009-11-12 | 2012-10-03 | 赛尔维他股份公司 | 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂 |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
| WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| WO2016035897A1 (ja) * | 2014-09-05 | 2016-03-10 | 日産化学工業株式会社 | 感光性無電解めっき下地剤 |
| US20240116897A1 (en) * | 2021-01-29 | 2024-04-11 | Korea Research Institute Of Chemical Technology | Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as active ingredient |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011236A (en) * | 1968-09-09 | 1977-03-08 | Merck & Co., Inc. | N-(benzimidazol-2-yl)arylcarboxamides as ultraviolet (uv) light absorbers |
| US4002623A (en) | 1974-08-07 | 1977-01-11 | Pfizer Inc. | Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines |
| UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| WO2001021160A2 (en) * | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| JP2004517080A (ja) * | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7132438B2 (en) * | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
| TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7338956B2 (en) * | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JP5001650B2 (ja) | 2003-07-11 | 2012-08-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンズイミダゾールカルボキサミド |
-
2004
- 2004-06-15 EP EP04739891A patent/EP1653951B1/en not_active Expired - Lifetime
- 2004-06-15 AT AT04739891T patent/ATE538787T1/de active
- 2004-06-15 US US10/564,185 patent/US7691886B2/en not_active Expired - Fee Related
- 2004-06-15 JP JP2006519783A patent/JP4823903B2/ja not_active Expired - Fee Related
- 2004-06-15 WO PCT/EP2004/006419 patent/WO2005004864A1/en not_active Ceased
- 2004-06-15 CA CA2531859A patent/CA2531859C/en not_active Expired - Fee Related
- 2004-06-15 ES ES04739891T patent/ES2380201T3/es not_active Expired - Lifetime
- 2004-07-08 AR ARP040102409A patent/AR045895A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR045895A1 (es) | 2005-11-16 |
| US20070010560A1 (en) | 2007-01-11 |
| US7691886B2 (en) | 2010-04-06 |
| EP1653951A1 (en) | 2006-05-10 |
| EP1653951B1 (en) | 2011-12-28 |
| JP2007513054A (ja) | 2007-05-24 |
| CA2531859A1 (en) | 2005-01-20 |
| ATE538787T1 (de) | 2012-01-15 |
| JP4823903B2 (ja) | 2011-11-24 |
| AU2004255403A1 (en) | 2005-01-20 |
| CA2531859C (en) | 2013-08-06 |
| WO2005004864A1 (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2380201T3 (es) | Derivados de benzimidazol | |
| AR045896A1 (es) | Bencimidazolcarboxamidas | |
| AR047585A1 (es) | Derivados de bisarilurea | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| AR054212A1 (es) | Derivados de bisarilurea sustituidos con heterociclos, composicion farmaceutica y un metodo para prepararla y compuestos intermediarios de sintesis | |
| ATE537169T1 (de) | Piperidin- und piperazinderivate als p2x3- antagonisten | |
| DOP2010000194A (es) | Derivados de oxadiazol activos sobre fosfato de esfingosina-1 | |
| ECSP067124A (es) | Inhibidores de cetp | |
| AR049418A1 (es) | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. | |
| CO5611128A2 (es) | Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales | |
| AR069637A1 (es) | Derivados de pirazinas | |
| HRP20090005T3 (hr) | Biciklički heterociklički spojevi kao inhibitori hiv integraze | |
| MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| AR043837A1 (es) | Pirazoles sustituidos | |
| PE20091673A1 (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilizacion | |
| EA200701076A1 (ru) | Антраниламидные инсектициды | |
| AR063151A1 (es) | Inhibidores de metaloproteasas de matriz | |
| CO5170512A1 (es) | Derivados de tetrahidroquinolin piperidina | |
| AR062299A1 (es) | Derivados de bencimidazol | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| DK0501892T3 (da) | Diazoterede heterocykliske N-substituerede derivater, der indeholder en biphenylmethylgruppe, fremstilling af derivaterne samt lægemidler indeholdende disse | |
| CO6351693A2 (es) | Nuevos derivados de acilamonobenzamida | |
| ATE538780T1 (de) | Medizinische zusammensetzung, enthaltend ein hmg- coa reduktase inhibitor und ein aminoalkohol derivat, als immunsuppressivum | |
| ECSP066609A (es) | Uso de derivados de n-arilhidracina para combatir pestes |